Genesis Therapeutics – headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego – is unifying AI and biotechnology to discover novel and breakthrough treatments for patients with severe and devastating conditions. We are using a proprietary state-of-the-art generative and predictive AI platform called GEMS (Genesis Exploration of Molecular Space), to accelerate and optimize small molecule drug discovery.

The GEMS platform integrates deep learning-based predictive models, molecular simulations, and molecular generative AI. GEMS accelerates hit ID through lead optimization and candidate selection by generating promising molecules for synthesis and experimental testing, and iterating this process through multiple cycles of AI-enabled discovery and optimization. 

We have leveraged GEMS to build an internal pipeline with multiple programs against high-value targets, including data-poor and canonically undruggable targets where GEMS is uniquely advantaged. In addition, Genesis has two AI platform collaborations across a range of therapeutic areas: Eli Lilly (signed in 2022) and Genentech (signed in 2020).

Genesis has raised over $280M in funding from top technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA's VC arm), BlackRock, and Menlo Ventures. We are rapidly growing our team with a variety of openings on our machine learning, computational chemistry, and software teams (primarily located in the Bay Area) and our chemistry, biology, and clinical teams (primarily located in San Diego). To learn more about Genesis Therapeutics, or current employment opportunities, please visit our website.

T. Rowe Price

Ulu Ventures

Felicis

Rock Springs Capital

Open Field Capital

Propagator Ventures

Radical Ventures

Jazz Venture Partners

Menlo Ventures

Jeffrey Rothschild

BlackRock

Fidelity

Andreessen Horowitz

Fidelity Management and Research Company

Genesis Therapeutics

Next week, Genesis’ CEO, Dr. Evan Feinberg, PhD, will speak at the 2024 WuXi AppTec Global Forum alongside fellow industry leaders to discuss how platform solutions, such as Genesis’ AI-enabled drug discovery platform, are driving the development of medicines that improve the lives of patients living with difficult-to-treat disease.

Learn more about the panel, “Delivering on Platform Solutions,” and the forum here: https://lnkd.in/ggbqGe2F

A few members of our technical team will be at MoML tomorrow. We’re looking forward to learning about the latest in molecular ML and connecting with old and new fiends. Come say hi 👋, find out what our team has been up to 🤓, and learn about opportunities at Genesis! 🚀

Genesis’ CEO and co-founder Evan Feinberg sat down with a16z Bio + Health and Health’s Vijay Pande, PhD on this week’s episode of Bio Eats World to discuss AI in small-molecule drug design and the founding of Genesis, from Evan’s early days at Stanford to the company’s recent $200M series B.

Listen to the podcast episode here: https://lnkd.in/g6-Zv-kQ

Genesis is excited to announce $200 million in Series B funding, which we’ll use to supercharge our AI platform and accelerate our pipeline with an eye toward the clinic.

Read more in today’s press release: https://lnkd.in/g3utJ3W9

CrUX Dataset

Google

Google Cloud

CrUX Top 10m

COVID-19

Google Cloud Global Multi-Region

New Relic

Amazon Elastic Load Balancing Sticky Session

CTO, Co-Founder

Ben Sklaroff

Founder and CEO

Evan Feinberg

Chief Business Officer

Will Mccarthy

Vice President of Finance

Donna Tran

Vice President/Business Strategy

James Schaeffer

Engineering

Advait Nagle

Associate Director, CADD Science

Andrea Bootsma

Sr Director Medicinal Chemistry

Brett Busch

Senior Director, Business Development and Strategy

Carl Tilbury

Business Management

Christopher Burke

Ekin Keserer

Kris Jenner

Vijay Pande

Greg Yap

CEO and Founder

Maruan Al-Shedivat

Director of Machine Learning

Alexander Izvorski

Research Scientist

CTO and Co-Founder

Private South San Francisco Companies

Information Technology Startups (Top 10K)

Western US Companies With Fewer Than 1000 Employees (Top 10K)

San Francisco Bay Area Companies With More Than 50 Employees (Top 10K)

Genesis Therapeutics is a company that has its roots in academic research, which serves as the foundational element of its growing portfolio of AI technologies. The company employs a combination of innovative deep neural networks, biophysical simulation techniques, and highly scalable computing infrastructure. This amalgamation of technologies is geared towards achieving remarkable results in molecular generation and property prediction, particularly in the field of drug discovery and molecular design.

Established in 2019 and headquartered in South San Francisco, California, Genesis Therapeutics focuses on leveraging innovative AI methodologies to enhance the efficiency and accuracy of molecular research. The company's approach holds promise in revolutionizing how molecules are generated and analyzed, potentially leading to advancements in drug development and related fields.

Series B - Genesis Therapeutic

Series A - Genesis Therapeutic

Seed Round - Genesis Therapeutic

Venture Round - Genesis Therapeutic

South San Francisco

California

United States

North America

Genesis Therapeutic

Gilead enters into AI drug discovery deal with Genesis Therapeutics (NASDAQ:GILD)

Gilead, Genesis Therapeutics to Use AI to Discover Novel Therapies

Genesis Therapeutics divulges new CDK2/cyclin A2 inhibitors

Genesis Therapeutics patents new PI3Kα mutant inhibitors

Fierce Medtech Names Genesis Therapeutics a “Fierce 15” Company of 2023

Fierce Medtech Names Genesis Therapeutics a "Fierce 15" Company of 2023

A generative and predictive AI platform used for small molecule drug discovery, focusing on novel and challenging targets.

A proprietary technology for predicting molecular properties like potency and ADMET, using deep learning and molecular simulations.

Enables exploration of chemical space to identify molecules for drug discovery, particularly for difficult targets.

Partnerships with companies like Eli Lilly and Genentech for drug discovery using Genesis's AI technologies.

Philippines

Asia

Circle Pharma Inc is a biotechnology company focused on the development of macrocycle therapeutics.

Circle Pharma Inc

Revitope Oncology Inc is a biotechnology company specializing in the development of precision cancer immunotherapies.

Revitope Oncology Inc

Genesis Therapeutics is a team of drug hunters, deep learning researchers, and software engineers collaborating to drive AI in biochemistry, discovering and developing new therapies for patients suffering from severe disorders.

news impact assignment basic	general	Feb 16, 2024 1:54 AM	1644987c
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	577d1435
crunchbase profile	general	Nov 25, 2024 11:35 AM	100c48ce
li profile	general	Feb 16, 2024 1:54 AM	a27c0c1d
translate crunchbase fundingrounds	general	Nov 25, 2024 2:14 PM	73b7fc1d
peers	general	Feb 16, 2024 1:54 AM	4b49bd89
news basic	general	Feb 16, 2024 1:54 AM	8e823276
bundesanzeiger	filings
financials download nd	financials
private financials	financials

AI:GENESISTHERAPEUTICS

Genesis Therapeutics